Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Jianhua Shi et al.|The Lancet Respiratory Medicine|2020Cited by 504
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Caicun Zhou, Jianhua Chen et al.|Journal of Thoracic Oncology|2021Cited by 311
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trialFeng Wang, Jianjun Zou|Journal of Hematology & Oncology|2020Cited by 136
FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathwayChao Liu, Qianming Du, Yan Zhao et al.|Cancer Letters|2019Cited by 67